Loading…
Bio-Techne Corporation is projected to rise to $87.87 by 2027, a +23% move from its current price of $71.30. TECH is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $69.71 | $71.34 | $73.01 | +0.06% |
| Jul 14 | $69.09 | $71.38 | $73.75 | +0.11% |
| Jul 15 | $68.62 | $71.42 | $74.34 | +0.17% |
| Jul 16 | $68.23 | $71.46 | $74.84 | +0.23% |
| Jul 17 | $67.90 | $71.50 | $75.30 | +0.28% |
| Jul 18 | $67.60 | $71.54 | $75.71 | +0.34% |
| Jul 19 | $67.34 | $71.58 | $76.10 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $67.34 | $71.58 | $76.10 | +0.40% |
| Week 2 | $65.91 | $71.87 | $78.36 | +0.80% |
| Week 3 | $64.90 | $72.15 | $80.22 | +1.20% |
| Week 4 | $64.10 | $72.44 | $81.87 | +1.60% |
| Week 5 | $63.43 | $72.73 | $83.39 | +2.01% |
| Week 6 | $62.86 | $73.02 | $84.82 | +2.41% |
| Week 7 | $62.36 | $73.31 | $86.19 | +2.82% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bio-Techne Corporation is a healthcare company that develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Bio-Techne Corporation (TECH) operates in the Healthcare sector as a provider of life science reagents, instruments, and services. The current price is $70.70 and the market cap is $11.07B. It ranks #875.
The 30-day range is $57.48 to $86.96, reflecting a healthy trading band around the current level. The technical picture shows bullish sentiment with RSI14 at 80, SMA50 at $52.77, and SMA200 at $57.62. Along with a stated support at $43.30 and resistance at $70.70, the chart context supports a positive near-term bias.
A major floor 40.3% below — a decisive break under it would weaken the trend.
The nearest floor, 30.2% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 20.1% above — clearing it would confirm fresh momentum.
Key TECH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TECH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $70.99 | Buy | $70.90 | Buy |
| MA 10 | $70.93 | Buy | $69.31 | Buy |
| MA 20 | $64.20 | Buy | $65.34 | Buy |
| MA 50 | $55.58 | Buy | $59.50 | Buy |
| MA 100 | $55.30 | Buy | $57.67 | Buy |
| MA 200 | $58.55 | Buy | $57.77 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 76.45 | Sell |
| Stoch RSI (14) | 92.88 | Sell |
| CCI (20) | 64.12 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.33 | Buy |
| ROC (12) | 26.73 | Buy |
| Bollinger %B (20,2) | 0.74 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 1.24 | Buy |
| Awesome (5,34) | 12.33 | Buy |
| Ultimate (7,14,28) | 74.89 | Sell |
| Momentum (10) | 0.60 | Buy |
| Aroon Osc (25) | 100.00 | Buy |
| Hull MA (9) | 71.10 | Buy |
| ADX (14) | 37.42 | Buy |
| ATR (14) | 1.18 | Info |
The 30-day picture is bullish, with RSI14 at 80 indicating strong momentum. The price has traded in a 30-day range of $57.48 to $86.96, with the current price near $70.70. Key moving averages show SMA50 at $52.77 and SMA200 at $57.62, framing a constructive near-term setup.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $43.30 | $71.30 | $95.15 | 0% | Neutral | |
| $70.95 | $87.87 | $114.48 | +23% | Bullish | |
| $79.50 | $100.77 | $135.57 | +41% | Bullish | |
| $103.04 | $133.13 | $183.67 | +87% | Bullish | |
| $116.96 | $153.69 | $216.57 | +116% | Bullish | |
| $118.72 | $158.41 | $227.41 | +122% | Bullish | |
| $133.52 | $180.71 | $263.79 | +153% | Bullish | |
| $140.28 | $192.40 | $285.14 | +170% | Bullish | |
| $150.15 | $208.54 | $313.42 | +192% | Bullish | |
| $184.10 | $258.79 | $394.03 | +263% | Bullish | |
| $243.95 | $361.99 | $582.14 | +408% | Bullish | |
| $520.36 | $846.06 | $1,474.49 | +10.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $43.30 | $71.30 | $84.57 | +0.00% |
| August 2026 | $62.51 | $73.48 | $88.46 | +3.05% |
| September 2026 | $63.51 | $75.09 | $91.26 | +2.19% |
| October 2026 | $62.52 | $74.30 | $91.02 | -1.05% |
| November 2026 | $62.63 | $74.74 | $92.19 | +0.60% |
| December 2026 | $63.98 | $76.67 | $95.15 | +2.58% |
Click any year to see its month-by-month TECH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TECH is projected to trade between $43.30 and $95.15, averaging $71.30 — a potential gain of 0% from today's $71.30. A consolidation phase looks the most probable path here.
Bio-Techne Corporation's 2027 outlook centres on $87.87, within a $70.95 to $114.48 range. That is up +23% on the projected 2026 average. That marks a +23% change versus current levels. Momentum favours further upside here.
By 2028, TECH could reach as high as $135.57, with a base case around $100.77 and support toward $79.50 — roughly +41% from $71.30. Buyers look set to stay in control over this stretch.
Expect TECH to range from $103.04 to $183.67 through 2029. The $133.13 average target implies a +87% move from current prices. That is up +32% on the projected 2028 average. Momentum favours further upside here.
The TECH price prediction for 2030 points to an average of $153.69 (low $116.96, high $216.57) — a potential gain of +116% on today's $71.30. Buyers look set to stay in control over this stretch.
In 2031, TECH is projected to trade between $118.72 and $227.41, averaging $158.41 — a potential gain of +122% from today's $71.30. That is up +3% on the projected 2030 average. Momentum favours further upside here.
Bio-Techne Corporation's 2032 outlook centres on $180.71, within a $133.52 to $263.79 range. That is up +14% on the projected 2031 average. That marks a +153% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, TECH could reach as high as $285.14, with a base case around $192.40 and support toward $140.28 — roughly +170% from $71.30. Momentum favours further upside here.
Expect TECH to range from $150.15 to $313.42 through 2034. The $208.54 average target implies a +192% move from current prices. That is up +8% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The TECH price prediction for 2035 points to an average of $258.79 (low $184.10, high $394.03) — a potential gain of +263% on today's $71.30. Momentum favours further upside here.
In 2040, TECH is projected to trade between $243.95 and $582.14, averaging $361.99 — a potential gain of +408% from today's $71.30. That is up +40% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Bio-Techne Corporation's 2050 outlook centres on $846.06, within a $520.36 to $1,474.49 range. That is up +134% on the projected 2040 average. That marks a +10.9x change versus current levels. Momentum favours further upside here.
Investing $1,000 in TECH today (≈ 14.025245 TECH) could be worth
$11,866.17
+$10,866.17 (+1087%) by 2050 · US Dollar
Based on the average projected TECH price of $846.06 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TECHwould be worth at today's price.
$1,000 invested in TECH on Jul 10, 2025 (≈ 18.378975 TECH) would be worth
$1,310.42
+$310.42 (+31.0%) today · 1.31× · US Dollar
Based on a TECH entry price of $54.41 vs. today's $71.3.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $70.83 | $1,006.64 | +0.7% |
| 1 month ago | $52.5 | $1,358.1 | +35.8% |
| 3 months ago | $55.54 | $1,283.76 | +28.4% |
| 6 months ago | $66.56 | $1,071.21 | +7.1% |
| 1 year ago | $54.41 | $1,310.42 | +31.0% |
| All time (5.0y) ago | $113.36 | $628.97 | -37.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TECH forecast.
Our base-case forecast reaches $140.00 around 2030.
Implied market cap at $140.00: $21.81B
From 2026 to 2029, the forecast shows a rising trend with multiple year-by-year milestones. In 2026, min $43.30, avg $70.70, max $96.01; ROI 0; sentiment NEUTRAL. In 2027, min $65.30, avg $83.32, max $113.07; ROI 17.8; sentiment NEUTRAL.
In 2028, min $74.90, avg $98.70, max $139.57; ROI 39.6; sentiment BULLISH. In 2029, min $97.91, avg $132.56, max $193.56; ROI 87.5; sentiment BULLISH. The forecast continues into 2030 with min $108.20, avg $150.03, max $225.07; ROI 112.2; sentiment BULLISH, followed by 2031 min $107.63, avg $152.56, max $234.32; ROI 115.8; sentiment BULLISH, 2032 min $118.90, avg $172.01, max $269.83; ROI 143.3; sentiment BULLISH, 2033 min $120.36, avg $177.53, max $283.85; ROI 151.1; sentiment BULLISH, 2034 min $128.15, avg $192.52, max $313.26; ROI 172.3; sentiment BULLISH, and 2035 min $160.21, avg $244.98, max $405.14; ROI 246.5; sentiment BULLISH.
Looking further ahead, 2040 shows min $199.51, avg $330.77, max $585.44; ROI 367.9; sentiment BULLISH, and 2050 shows min $405.00, avg $774.01, max $1,511.30; ROI 994.8; sentiment BULLISH. These are estimates and not guarantees, and depend on market conditions and demand for Bio-Techne’s products and services.
Tap a question to reveal the answer.
In 2030 the forecast shows min $108.20, avg $150.03, max $225.07; ROI 112.2; sentiment BULLISH.
The forecast shows a rising path with 2026 avg $70.70 and 2029 avg $132.56, culminating in 2040 avg $330.77 and 2050 avg $774.01; ROI values reach 112.2 (2030), 367.9 (2040), and 994.8 (2050); sentiment turns bullish in later years. These figures are estimates and not guarantees.
Yes. The forecast shows 2028 max $139.57 and 2029 avg $132.56, with 2028 max above $100. The path includes 2027 avg $83.32 and 2029 avg $132.56.
Current price is $70.70 and market cap is $11.07B.
The 30-day range is $57.48 to $86.96, with RSI14 at 80. The stock shows support at $43.30 and resistance at $70.70.
Bio-Techne Corporation Community Discussion
0Share your Bio-Techne Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.